BioSpace News Archive

Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated.

Paragonix Technologies, a pioneer in organ transplant technologies and organ procurement services, has successfully completed the world’s first-in-human case utilizing its newest donor lung preservation technology, the BAROguard™ Donor Lung Preservation System, which received FDA 510(k) clearance in August 2023.

FORE Biotherapeutics reported updated safety and efficacy data from the Phase 1/2a clinical trial evaluating plixorafenib, a novel, investigational, small-molecule, next-generation, orally available selective inhibitor of BRAF alterations.

Sanyou’s “STAL Innovative Biologics Drug Discovery Platform” is a significant advancement in the field of drug discovery.

Asep Medical Holdings Inc. is pleased to announce it is in the final stage of its approval process for the draft registration statement on Form F-1 which was filed with the U.S. Securities and Exchange Commission for its planned listing and trading of common shares on the NASDAQ stock exchange.

Bayer is voluntarily recalling one lot of Vitrakvi® Oral Solution 20 mg/mL in 100mL glass bottles to the consumer/user level.

CG Pharmaceuticals announces the commencement of Phase 2 study for metastatic pancreatic ductal adenocarcinoma with the recommended Phase 2 dose of ivaltinostat.

Medtronic plc announced that the United States Food and Drug Administration has approved the Symplicity Spyral™ renal denervation system, also known as the Symplicity™ blood pressure procedure, for the treatment of hypertension.